+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15

Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15

Plos One 3(5): E2241

NK cells have been long time considered as cytotoxic lymphocytes competent in killing virus-infected cells and tumors. However, NK cells may also play essential immuno-regulatory functions. In this context, the real existence of a defined NK subset with negative regulatory properties has been hypothesized but never clearly demonstrated. Herein, we show the in vitro generation from human peripheral blood haematopoietic progenitors (PB-HP), of a novel subset of non-cytolytic NK cells displaying a mature phenotype and remarkable immuno-regulatory functions (NK-ireg). The main functional hallmark of these NK-ireg cells is represented by the surface expression/release of HLA-G, a major immunosuppressive molecule. In addition, NK-ireg cells secrete two powerful immuno-regulatory factors: IL-10 and IL-21. Through these factors, NK-ireg cells act as effectors of the down-regulation of the immune response: reconverting mature myeloid DC (mDC) into immature/tolerogenic DC, blocking cytolytic functions on conventional NK cells and inducing HLA-G membrane expression on PB-derived monocytes. The generation of "NK-ireg" cells is obtained, by default, in culture conditions favouring cell-to-cell contacts, and it is strictly dependent on reciprocal trans-presentation of membrane-bound IL-15 forms constitutively and selectively expressed by human CD34(+) PB-HP. Finally, a small subset of NKp46(+) HLA-G(+) IL-10(+) is detected within freshly isolated decidual NK cells, suggesting that these cells could represent an in vivo counterpart of the NK-ireg cells. In conclusion, NK-ireg cells represent a novel truly differentiated non-cytolytic NK subset with a self-sustainable phenotype (CD56(+) CD16(+) NKp30(+) NKp44(+) NKp46(+) CD94(+) CD69(+) CCR7(+)) generated from specific pSTAT6(+) GATA3(+) precursors. NK-ireg cells could be employed to develop new immuno-suppressive strategies in autoimmune diseases, transplant rejection or graft versus host diseases. In addition, NK-ireg cells can be easily derived from peripheral blood of the patients and could constitute an autologous biotherapic tool to be used combined or in alternative to other immuno-regulatory cells.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053373529

Download citation: RISBibTeXText

PMID: 18493613

DOI: 10.1371/journal.pone.0002241

Related references

Membrane-bound IL-15 stimulation on peripheral blood natural kiler progenitors leads to the generation of an adherent subset co-expressing dendritic cells and natural kiler functional markers. Haematologica 96(5): 762-766, 2011

Purified unfractionated G-CSF/chemotherapy mobilized CD34+ peripheral blood progenitors and not bone marrow CD34+ progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. British Journal of Haematology 96(1): 55-63, 1997

CD34+/CD33- subset and hemopoietic recovery after transplantation with unfractionated or purified peripheral blood hemopoietic progenitors. British Journal of Haematology 93(SUPPL 2): 79, 1996

Efficient ex vivo generation of human dendritic cells from mobilized CD34+ peripheral blood progenitors. International Journal of Hematology 74(3): 287-296, 2001

Plerixafor + G-CSF vs Placebo + G-CSF for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low Peripheral Blood CD34+ Cell Count Results of a Subset Analysis of a Randomized Trial. 2012

Generation of induced pluripotent stem cells from peripheral blood CD34+ hematopoietic progenitors of a 31year old healthy woman. Stem Cell Research 20: 91-93, 2017

Large-scale generation of megakaryocytic cells from CD34+ peripheral blood progenitors for clinical use after high-dose chemotherapy. Blood 90(10 SUPPL 1 PART 1): 536A, Nov 15, 1997

Massive ex-vivo generation of immunostimulatory dendritic cells from CD34+ progenitors mobilized in peripheral blood by anticancer chemotherapy and cytokines. Experimental Hematology 23(8): 837, 1995

Total CD34+ cell content and CD34+CD33- subset predict time to neutrophil and platelet engraftment and hospital discharge in patients following high-dose chemotherapy with primed peripheral blood progenitor cells. Blood 84(10 SUPPL 1): 88A, 1994

Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. British Journal Of Haematology. 96(1): 64-69, 1997

Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils. Journal of Leukocyte Biology 87(2): 291-300, 2010

Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells. Annals of Hematology 79(1): 13-19, 2000

Comparative assays of megakaryocyte progenitors in CD34+ peripheral blood progenitor cell fractions. Progress in Clinical and Biological Research 389: 415-420, 1994

A neutralizing anti-TGF-beta1 antibody promotes proliferation of CD34+Thy-1+ peripheral blood progenitors and increases the number of transduced progenitors. Experimental Hematology 26(5): 374-381, 1998

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental Medicine 185(1): 111-120, 1997